BMO Capital analyst Evan Seigerman lowered the firm’s price target on Novo Nordisk to $156 from $160 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. Looking at script growth for Ozempic and Wegovy from Q2, the firm sees 4% and 24% growth, respectively, but while growth continues to be impressive, sell-side estimates may now be catching up to this growth, the analyst tells investors in a research note. Novo’s Victoza scripts have declined nearly 50% from Q2 however as patients and providers transition to more efficacious agents Mounjaro / Ozempic, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- United Air reports Q3 beat, Amazon unveils nuclear energy pacts: Morning Buzz
- Novo Nordisk halts the production of insulin pens, The Guardian reports
- Novo Nordisk Initiates Major Share Repurchase Program
- Barclays says GLP-1 compounding bear case not reflected in WeightWatchers shares
- WeightWatchers (NASDAQ:WW) Stock Jumps 40% on Plan to Sell Obesity Medications
Questions or Comments about the article? Write to editor@tipranks.com